Pay in 4 interest-free payments of $6.27 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Your body produces GLP-1 naturally, primarily after meals
Youle M, et al
Can a GLP-1 Improve Insulin Resistance
Bouaziz, J
Participants randomized to retatrutide initiated treatment with 2 mg once weekly and increased the dose in a step-wise approach every four weeks until reaching the target dose of 9 mg (via steps at 2 mg, 4 mg and 6 mg) or 12 mg (via steps at 2 mg, 4 mg, 6 mg and 9 mg)
IP portfolio composition (approximate): Composition-of-matter patents: expired 2016 (US) and 2018 (EU) Manufacturing process patents: extended effective protection through 2022 and beyond in some jurisdictions Formulation patents: citrate-free high-concentration formulation, enabling the Humira CF transition Device patents: proprietary auto-injector design Method-of-use patents: spanning 14 approved indications including RA, Crohns disease, psoriasis, uveitis, and pediatric extensions IP valuation framework: At peak, Humiras patent portfolio represented approximately $15-18 billion in net present value of protected cash flows (using a 10% discount rate, a 75% probability of litigation success based on historical BPCIA outcomes, and a 3-year median delay from patent challenge to market entry)
US$ 20.59
US$ 27.23
US$ 27.99
US$ 28.48
US$ 29.83
US$ 23.26
US$ 26.15
